Market Closed -
Nyse
04:00:02 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
229
USD
|
+0.54%
|
|
+0.99%
|
-3.12%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,416
|
12,366
|
18,969
|
11,086
|
12,127
|
11,761
|
-
|
-
|
Enterprise Value (EV)
1 |
9,066
|
14,117
|
21,394
|
13,564
|
14,497
|
13,745
|
13,274
|
12,803
|
P/E ratio
|
29.9
x
|
34.5
x
|
49.5
x
|
23
x
|
25.6
x
|
28.3
x
|
23
x
|
19
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.83
x
|
4.23
x
|
5.36
x
|
2.79
x
|
2.94
x
|
2.78
x
|
2.59
x
|
2.39
x
|
EV / Revenue
|
3.46
x
|
4.83
x
|
6.04
x
|
3.41
x
|
3.51
x
|
3.25
x
|
2.92
x
|
2.61
x
|
EV / EBITDA
|
15
x
|
20.1
x
|
24.3
x
|
13.7
x
|
14.3
x
|
12.9
x
|
11.3
x
|
9.86
x
|
EV / FCF
|
26.6
x
|
37.1
x
|
40.2
x
|
46
x
|
39.7
x
|
30.2
x
|
23.3
x
|
19.8
x
|
FCF Yield
|
3.75%
|
2.69%
|
2.49%
|
2.17%
|
2.52%
|
3.31%
|
4.3%
|
5.06%
|
Price to Book
|
4.55
x
|
5.85
x
|
7.46
x
|
3.73
x
|
3.37
x
|
2.9
x
|
2.53
x
|
2.18
x
|
Nbr of stocks (in thousands)
|
48,839
|
49,743
|
50,464
|
50,879
|
51,297
|
51,350
|
-
|
-
|
Reference price
2 |
151.8
|
248.6
|
375.9
|
217.9
|
236.4
|
229.0
|
229.0
|
229.0
|
Announcement Date
|
2/11/20
|
2/17/21
|
2/16/22
|
2/22/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,621
|
2,924
|
3,540
|
3,976
|
4,129
|
4,223
|
4,544
|
4,912
|
EBITDA
1 |
604.4
|
701.3
|
879.5
|
990.9
|
1,013
|
1,063
|
1,176
|
1,298
|
EBIT
1 |
497.2
|
585
|
742.1
|
834
|
838.8
|
876.8
|
978.2
|
1,086
|
Operating Margin
|
18.97%
|
20.01%
|
20.96%
|
20.97%
|
20.31%
|
20.76%
|
21.53%
|
22.12%
|
Earnings before Tax (EBT)
1 |
304.1
|
447.1
|
480.7
|
623
|
581.3
|
552.4
|
692.7
|
821.5
|
Net income
1 |
252
|
364.3
|
391
|
486.2
|
474.6
|
419.7
|
525.1
|
629
|
Net margin
|
9.61%
|
12.46%
|
11.04%
|
12.23%
|
11.49%
|
9.94%
|
11.56%
|
12.8%
|
EPS
2 |
5.070
|
7.200
|
7.600
|
9.480
|
9.220
|
8.103
|
9.950
|
12.07
|
Free Cash Flow
1 |
340.4
|
380
|
532
|
294.9
|
365.4
|
455.3
|
570.8
|
647.8
|
FCF margin
|
12.99%
|
13%
|
15.03%
|
7.42%
|
8.85%
|
10.78%
|
12.56%
|
13.19%
|
FCF Conversion (EBITDA)
|
56.32%
|
54.19%
|
60.5%
|
29.76%
|
36.06%
|
42.84%
|
48.54%
|
49.91%
|
FCF Conversion (Net income)
|
135.08%
|
104.31%
|
136.07%
|
60.65%
|
76.98%
|
108.47%
|
108.7%
|
102.99%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/11/20
|
2/17/21
|
2/16/22
|
2/22/23
|
2/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
895.9
|
905
|
913.9
|
973.1
|
989.2
|
1,100
|
1,029
|
1,060
|
1,027
|
1,013
|
993.5
|
1,042
|
1,075
|
1,113
|
1,069
|
EBITDA
1 |
226.3
|
226.9
|
233.2
|
250.4
|
240.4
|
266.9
|
259.8
|
259.5
|
255.4
|
238.5
|
222.1
|
257.7
|
283.2
|
300.2
|
245
|
EBIT
1 |
191.8
|
189.1
|
196
|
211.7
|
201.4
|
224.8
|
217.8
|
216.2
|
210.9
|
193.9
|
177.8
|
212.3
|
236.5
|
250.7
|
203.3
|
Operating Margin
|
21.41%
|
20.89%
|
21.45%
|
21.75%
|
20.36%
|
20.44%
|
21.16%
|
20.4%
|
20.54%
|
19.14%
|
17.89%
|
20.37%
|
21.99%
|
22.52%
|
19.03%
|
Earnings before Tax (EBT)
1 |
123.3
|
163.6
|
110.8
|
144.1
|
123.1
|
244.9
|
131
|
128.7
|
112.9
|
208.7
|
96.3
|
130.2
|
156.9
|
172.8
|
145.2
|
Net income
1 |
103.4
|
137.6
|
93.02
|
109.3
|
96.47
|
187.4
|
103.1
|
97.02
|
87.39
|
187.1
|
71.21
|
99.9
|
119.8
|
131.8
|
102.8
|
Net margin
|
11.54%
|
15.2%
|
10.18%
|
11.23%
|
9.75%
|
17.04%
|
10.02%
|
9.15%
|
8.51%
|
18.46%
|
7.17%
|
9.58%
|
11.14%
|
11.84%
|
9.62%
|
EPS
2 |
2.010
|
2.670
|
1.810
|
2.130
|
1.880
|
3.650
|
2.010
|
1.890
|
1.690
|
3.620
|
1.350
|
1.918
|
2.305
|
2.522
|
1.960
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
2/16/22
|
5/4/22
|
8/3/22
|
11/2/22
|
2/22/23
|
5/11/23
|
8/9/23
|
11/8/23
|
2/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
1,650
|
1,751
|
2,425
|
2,477
|
2,370
|
1,985
|
1,513
|
1,042
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
2.73
x
|
2.497
x
|
2.758
x
|
2.5
x
|
2.339
x
|
1.867
x
|
1.287
x
|
0.8032
x
|
Free Cash Flow
1 |
340
|
380
|
532
|
295
|
365
|
455
|
571
|
648
|
ROE (net income / shareholders' equity)
|
22.7%
|
22%
|
22.8%
|
20.7%
|
16.7%
|
14.9%
|
14.6%
|
13.9%
|
ROA (Net income/ Total Assets)
|
7.82%
|
8.08%
|
8.48%
|
7.8%
|
6.95%
|
7.34%
|
8.04%
|
8.61%
|
Assets
1 |
3,222
|
4,508
|
4,612
|
6,232
|
6,830
|
5,716
|
6,533
|
7,303
|
Book Value Per Share
2 |
33.40
|
42.50
|
50.40
|
58.40
|
70.10
|
78.90
|
90.70
|
105.0
|
Cash Flow per Share
2 |
9.680
|
10.80
|
15.10
|
12.10
|
13.30
|
14.50
|
16.50
|
18.40
|
Capex
1 |
141
|
167
|
229
|
325
|
319
|
309
|
328
|
344
|
Capex / Sales
|
5.36%
|
5.7%
|
6.46%
|
8.17%
|
7.71%
|
7.32%
|
7.21%
|
7%
|
Announcement Date
|
2/11/20
|
2/17/21
|
2/16/22
|
2/22/23
|
2/14/24
|
-
|
-
|
-
|
Average target price
270.7
USD Spread / Average Target +18.18% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.12% | 11.76B | | +1.51% | 42.75B | | +8.57% | 41.34B | | +49.22% | 41.61B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | +6.35% | 11B | | -16.98% | 10.07B |
Other Biotechnology & Medical Research
|